 Flutamide has also been employed as an antiandrogen in transgender women, with at least two treatment centers reporting its frequent use.In the clinical studies of nilutamide for transgender hormone therapy, the medication, given alone and not in combination with an estrogen, induced observable signs of clinical feminization in young transgender women (ages 19 to 33 years) within 8 weeks.These changes included breast development, decreased male-pattern hair, decreased spontaneous erections and sex drive, and positive psychological and emotional changes.